Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, ...

Annexon Biosciences: Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory ...

Warning issued to anyone watching tonight's solar eclipse

Health and space experts are warning that even a brief glance at the event without proper protection could cause permanent damage.
News Medical

AI took on doctors in simulated video consultations, and the results were striking

A Gemini-powered medical AI combined sight, sound, and clinical reasoning to match or outperform physicians on key measures in simulated video consultations, while revealing where human connection and ...
Seeking Alpha

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Good morning, everyone, and welcome to the Annexon Business Update Call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Annexon website ...

VB-MAPP and objective measurement for autism: How eye-tracking complements verbal behavior assessment

How eye-tracking complements verbal behavior assessment  The VB-MAPP is one of the most widely used assessments in applied behavior analysis, and for good reason. It gives BCBAs a structured, […] ...